Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
8 studies found for:    EPOR
Show Display Options
Rank Status Study
1 Withdrawn A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies
Condition: Anemia
Intervention: Drug: No intervention
2 Active, not recruiting Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens
Condition: Cancer
3 Completed Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia
Conditions: CABG;   Coronary Artery Disease
Interventions: Drug: Epoetin alpha;   Drug: NaCl 0.9%
4 Completed A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
Condition: Anemia
Intervention: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
5 Recruiting Molecular Biology of Polycythemia and Thrombocytosis
Conditions: Polycythemia;   Thrombocytosis
6 Completed The Role of Erythropoietin in Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
7 Completed Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction
Condition: Acute Myocardial Infarction
Intervention: Drug: methoxy-polyethyleneglycol epoetin beta
8 Completed Comparison Among Erythropoietin Stimulating Agents
Condition: Anemia of End Stage Renal Disease
Interventions: Drug: Epoetin alpha or beta (Epoetin group);   Drug: Darbepoetin alfa;   Drug: Methoxy polyethylene glycol-epoetin beta

Indicates status has not been verified in more than two years